| |
|
|
|
|
|
 |
| |
|
¿Àťī¸£ÇÉÁ¡¾È¾×1%(ÇÊ·ÎÄ«¸£ÇÉ¿°»ê¿°) OCUCARPINE EYE.[Pilocarpine HCl]
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643901080[A05001901]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml(2016.10.01)(ÇöÀç¾à°¡)
\123 ¿ø/1ml(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¼ö¿ë¼º Á¡¾È¾× [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
10ml
|
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 10¹Ð¸®¸®ÅÍ |
1 °³ |
º´ |
8806439010809 |
8806439010816 |
|
|
| ÁÖ¼ººÐÄÚµå |
212302COS
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
³ì³»Àå, Áø´Ü ¶Ç´Â Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â Ãൿ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ȸ 1-2¹æ¿ï 1ÀÏ 3-5ȸ Á¡¾ÈÇÑ´Ù. Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ȫä¿° ȯÀÚ(Ãൿ¿¡ ÀÇÇØ ȫäÀÇ À¯ÂøÀ» ÀÏÀ¸Å³ ¼ö ÀÖ°í ¶ÇÇÑ ¿°ÁõÀ» ¾ÇȽÃų¼ö ÀÖ´Ù.)
2) ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ȯÀÚ.
3) ¾Ç¼º ³ì³»Àå°ú ¸ðµç ¼öÁ¤Ã¼¼º ¼Ó¹ß¼º ³ì³»Àå ȯÀÚ
4) µ¿°øÇùÂø ³ì³»Àå ȯÀÚ
5) °¢¸· ÈÑ¼Õ È¯ÀÚ
|
| ½ÅÁßÅõ¿© |
1) ±â°üÁöõ½Ä ȯÀÚ(õ½Ä¹ßÀÛÀ» ¾ÇȽÃų ¼ö ÀÖ´Ù.)
2) ¸Á¸·¹Ú¸®ÀÇ À§ÇèÀÌ Àִ ȯÀÚ
3) ½ÉºÎÀüÁõ ȯÀÚ
4) °©»ó¼± ±â´ÉÇ×ÁøÁõ ȯÀÚ
5) ÀåÆó»ö µî ¼ÒȰü ÇùÂø ȯÀÚ
6) ½ÊÀÌÁöÀå ±Ë¾ç ȯÀÚ
7) ¿ä·ÎÀå¾Ö·Î ÀÎÇÑ ¿ä·ÎÆó»ö ȯÀÚ
8) º¯ºñ·Î ÀÎÇÑ ¹èº¯Àå¾Ö ȯÀÚ
9) ÆÄŲ½¼º´ ȯÀÚ
10) ¼Ò¾Æ
11) ±Ù½Ã ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
Àü½ÅÁõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ¾ÆÆ®·ÎÇÉȲ»ê¿°¼öȹ°ÀÇ Åõ¿©µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
1) °ú¹ÎÁõ : ¾È°Ë¿°, °¡·Á¿ò µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
2) ´« : µå¹°°Ô ¹é³»Àå, °á¸·ÃæÇ÷ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖ´Ù. ´«¹°ºÐºñÀÇ Áõ°¡, ÀÚÅë, Ç¥¸é °¢¸·¿°, ÀϽÃÀûÀÎ ±Ù½ÃÀÇ ¿ø±ÙÁ¶ÀýÀå¾Ö, ÀÛ¿°¨, ¸ð¾çü ¿¬Ãà, ¾È¿ÍÀ§ÀÇ µÎÅë µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ³ì³»Àå Ä¡·á¿¡ ÀÇÇØ °¢¸· À°¾Æ°¡ »ý±æ ¼ö ÀÖ´Ù. °í·ÉÀÚ³ª ·»Áî ȥŹÀÚ¿¡¼ ¾îµÎ¿î Á¶¸íÇÏ¿¡¼ ½Ã·ÂÀúÇϰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. Àå±â »ç¿ë½Ã ·»ÁîȥŹ, ¸Á¸·±Õ¿ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) Á¤½Å½Å°æ°è : Âø¶õ, ±â¾ïÀå¾Ö µîÀÇ Á¤½ÅÁõ»óÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
4) ¼øÈ¯±â°è : ½ÉºÎÀüÁõ, Ç÷¾ÐÁõ°¡ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) È£Èí±â°è : ÆóºÎÁ¾ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ¼Òȱâ°è : ¼³»ç, ±¸¿ª, ±¸Åä µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) ±âŸ : ¹ßÇÑ, Ÿ¾×ºÐºñ, ±ÙÀ°¾àȰ¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç óÀ½ Ä¡·á¸¦ ½ÃÀÛÇÒ ¶§ µ¿°ø¼öÃàÀÇ °á°ú·Î °æ¹ÌÇÑ ¸ð¾çü °æ·ÃÀÌ ÀϾ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ¼÷»ç¸ÞÅä´½¿°È¹°¼öȹ° °è¿ÀÇ ±ÙÀ°ÀÌ¿ÏÁ¦¿Í º´¿ëÅõ¿©½Ã È¿°ú°¡ Áö¼Ó, ¿¬ÀåµÈ´Ù.
2) Å¥¶ó·¹ °è¿ÀÇ ±ÙÀ°ÀÌ¿ÏÁ¦¿Í º´¿ëÅõ¿©½Ã È¿°ú°¡ °¨¼ÒÇÑ´Ù.
3) °½É¹è´çü¿Í º´¿ëÅõ¿©½Ã ÈïºÐÈ¿°ú°¡ Áö¼ÓµÇ°í ¸Æ¹ÚÀÌ °¨¼ÒÇÑ´Ù.
4) Äû´Ïµò°ú ÇÁ·ÎÄ«Àξƹ̵å¿Í º´¿ëÅõ¿©½Ã ºÎ±³°¨½Å°æ ÀÚ±ØÁ¦ÀÇ ¹ÝÀÀ·ÂÀÌ °¨¼ÒÇÑ´Ù.
5) ´Ù¸¥ ÃൿÁ¦, º£Å¸Â÷´ÜÁ¦, ź»ê Å»¼ö¼Ò È¿¼Ò ÀúÇØÁ¦, ±³°¨½Å°æ È¿´ÉÁ¦ ¶Ç´Â °ú»ïÅõ¾ÐÁ¦¿Í º´¿ëÅõ¿©ÇÒ ¼ö ÀÖ´Ù.
6) ¿Ü°ú¼ö¼ú½Ã ÀÌ ¾àÀº ¸¶ÃëÁ¦ÀÇ È¿·ÂÀ» Áõ°½Ãų ¼ö ÀÖÀ¸¹Ç·Î »ç¿ëÀ» ÇÇÇÑ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[Á¡¾È¾×] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Pilocarpine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Pilocarpine is a cholinergic parasympathomimetic agent. It increase secretion by the exocrine glands, and produces contraction of the iris sphincter muscle and ciliary muscle (when given topically to the eyes) by mainly stimulating muscarinic receptors.
|
| Pharmacology |
Pilocarpine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Pilocarpine is a choline ester miotic and a positively charged quaternary ammonium compound. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal, gastric, pancreatic, and intestinal glands and the mucous cells of the respiratory tract may be stimulated. When applied topically to the eye as a single dose it causes miosis, spasm of accommodation, and may cause a transitory rise in intraocular pressure followed by a more persistent fall. Dose-related smooth muscle stimulation of the intestinal tract may cause increased tone, increased motility, spasm, and tenesmus. Bronchial smooth muscle tone may increase. The tone and motility of urinary tract, gallbladder, and biliary duct smooth muscle may be enhanced. Pilocarpine may have paradoxical effects on the cardiovascular system. The expected effect of a muscarinic agonist is vasodepression, but administration of pilocarpine may produce hypertension after a brief episode of hypotension. Bradycardia and tachycardia have both been reported with use of pilocarpine.
|
| Metabolism |
Pilocarpine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2A6 (CYP2A6)
|
| Half-life |
Pilocarpine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 0.76 hours
|
| Absorption |
Pilocarpine¿¡ ´ëÇÑ Absorption Á¤º¸ There was a decrease in the rate of absorption of pilocarpine from SALAGEN Tablets when taken with a high fat meal by 12 healthy male volunteers
|
| Pharmacokinetics |
Pilocarpine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Á¡¾È :
- Ãൿ :
- ÀÛ¿ë¹ßÇö½Ã°£ : 10-30ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-8 ½Ã°£
- ¾È¾Ð °¨¼Ò :
- ÀÛ¿ë¹ßÇö½Ã°£ : 1½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-12 ½Ã°£
- OcusertR Pilo »ðÀÔ :
- Ãൿ ¹ßÇö½Ã°£ : 1.5-2 ½Ã°£
- ¾È¾Ð °¨¼Ò :
- ÀÛ¿ë¹ßÇö½Ã°£ : 1.5-2 ½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 1ÁÖÀÏ
|
| Biotransformation |
Pilocarpine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Possibly occurs at the neuronal synapses and in the plasma
|
| Toxicity |
Pilocarpine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Pilocarpine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Pilocarpine¿¡ ´ëÇÑ Description Á¤º¸ A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma. [PubChem]
|
| Dosage Form |
Pilocarpine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Gel OphthalmicLiquid OphthalmicLiquid OralSolution OphthalmicSolution / drops OralTablet Oral
|
| Drug Category |
Pilocarpine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Cholinergic AgentsMioticsMuscarinic Agonists
|
| Smiles String Canonical |
Pilocarpine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCC1C(COC1=O)CC1=CN=CN1C
|
| Smiles String Isomeric |
Pilocarpine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC[C@H]1[C@H](COC1=O)CC1=CN=CN1C
|
| InChI Identifier |
Pilocarpine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1
|
| Chemical IUPAC Name |
Pilocarpine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
|
| Drug-Induced Toxicity Related Proteins |
PILOCARPINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Mu-type opioid receptor Drug:pilocarpine Toxicity:pilocarpine-induced seizures. [¹Ù·Î°¡±â] Replated Protein:Delta-type opioid receptor Drug:pilocarpine Toxicity:pilocarpine-induced seizures. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-09-01
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|